- Home
- SKBL vs ATXS Comparison
SKBL vs ATXS Comparison
Compare SKBL & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKBL
- ATXS
- Stock Information
- Founded
- SKBL 2012
- ATXS 2008
- Country
- SKBL Hong Kong
- ATXS United States
- Employees
- SKBL N/A
- ATXS N/A
- Industry
- SKBL
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- SKBL
- ATXS Health Care
- Exchange
- SKBL NYSE
- ATXS Nasdaq
- Market Cap
- SKBL 389.6M
- ATXS 401.2M
- IPO Year
- SKBL 2025
- ATXS 2015
- Fundamental
- Price
- SKBL $11.34
- ATXS $4.04
- Analyst Decision
- SKBL
- ATXS Strong Buy
- Analyst Count
- SKBL 0
- ATXS 5
- Target Price
- SKBL N/A
- ATXS $26.60
- AVG Volume (30 Days)
- SKBL 775.8K
- ATXS 369.7K
- Earning Date
- SKBL 01-01-0001
- ATXS 05-08-2025
- Dividend Yield
- SKBL N/A
- ATXS N/A
- EPS Growth
- SKBL N/A
- ATXS N/A
- EPS
- SKBL 0.03
- ATXS N/A
- Revenue
- SKBL $49,638,709.00
- ATXS N/A
- Revenue This Year
- SKBL N/A
- ATXS N/A
- Revenue Next Year
- SKBL N/A
- ATXS N/A
- P/E Ratio
- SKBL $364.31
- ATXS N/A
- Revenue Growth
- SKBL 9.58
- ATXS N/A
- 52 Week Low
- SKBL $6.93
- ATXS $3.56
- 52 Week High
- SKBL $13.40
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- SKBL N/A
- ATXS 28.96
- Support Level
- SKBL N/A
- ATXS $3.56
- Resistance Level
- SKBL N/A
- ATXS $4.39
- Average True Range (ATR)
- SKBL 0.00
- ATXS 0.42
- MACD
- SKBL 0.00
- ATXS -0.04
- Stochastic Oscillator
- SKBL 0.00
- ATXS 22.61
About SKBL SKYLINE BUILDERS GROUP HOLDING LIMI
Skyline Builders Group Holding Ltd is an holding company operates through its subsidiary. It is a Public Works Contractor company undertaking roads and drainage in Hong Kong. Its construction activities mainly include public civil engineering works, such as road and drainage works, in Hong Kong.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.